UPDATE 3-Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. Food and Drug Administration (FDA) gave the green light to its semaglutide drug.